Evolent reposted this
Recent years have yielded remarkable strides in oncology, particularly with chimeric antigen receptor (CAR) T-cell and bispecific T-cell engager (BiTE) therapies. While these two therapies were primarily approved for hematologic malignancies, their potential in treating solid tumors provides another option for patients. In the June issue of the AJMC - The American Journal of Managed Care’s Evidence-Based Oncology, our team of Evolent oncology experts explains why increased access and decreased time to administration will steer many patients toward BiTE and away from CAR T therapy, even though the latter will remain an option in a patient’s care plan. See the full article co-authored by colleagues Terra Wonsettler, Pharm.D., MBA; Sang Chau PharmD, BCOP; Justin Tse, PharmD, BCOP; Amy VanGalder, PharmD, BCOP; and Garrick Wong, PharmD. Link to article here: https://lnkd.in/et4JeRYk #healthcare #health #oncology #genetics Evolent
